NEW YORK, Oct. 5, 2016 /PRNewswire/ -- Pomerantz LLP
is investigating claims on behalf of investors of Trinity Biotech
plc ("Trinity" or the "Company") (NASDAQ: TRIB) (ISIN:
US896483066). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com
or 888-476-6529, ext. 9980.
The investigation concerns whether Trinity and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
[Click here to join a class action]
On October 4, 2016, pre-market,
the Company announced that it was withdrawing its 510(k) premarket
notification submission for the Meritas Troponin-I Test and Meritas
Point-of-Care Analyzer on the advice of the U.S. Food and Drug
Administration. Citing the application withdrawal, Trinity
also stated it would reduce its spending by nearly 85%, to
$1.5 million from $9 million a year, and that it would close a
Swedish facility, eliminating 40 jobs.
On this news, Trinity's share price fell $6.53, or 50.27%, to close at $6.46 on October 4,
2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-trinity-biotech-plc--trib-300339819.html
SOURCE Pomerantz LLP